Study:Â #Â 6850Â entitledÂ AÂ sequenced Â behavioralÂ andÂ medicationÂ in terventionÂ forÂ cocaineÂ dependenceÂ 
Â 
PI:Â [INVESTIGATOR_271203]Â R.Â LevinÂ 
NCT#Â  [STUDY_ID_REMOVED] Â 
StudyÂ ProtocolÂ Date:Â 10/31/2013Â Â 
 
 
 
  
 
 
 
  
 
  
 
 
 
6LJQHGFRS\RQILOHDW,5%   Y1HZ<RUN6WDWH3V\FKLDWULF,QVWLWXWH
,QVWLWXWLRQDO5HYLHZ%RDUG

2FWREHU


7R  'U)UDQFHV/HYLQ
)URP'U(GZDUG1XQHV&KDLUPDQ

6XEMHFW$SSURYDO1RWLFH 
 
 
<RXUSURWRFROHQWLWOHG$6HTXHQFHG%HKDYLRUDODQG0HG LFDWLRQ,QWHUYHQWLRQIRU
&RFDLQH'HSHQGHQFH 3URWRFROYHUVLRQGDWHD QGFRQVHQWIRUPVKDYHEHHQDSSU RYHGE\WKH
1HZ<RUN6WDWH3V\FKLDWULF,QVWLWXWH&ROXPELD8QLYHUVLW\'HSD UWPHQWRI3V\FKLDWU\,QVWLWXWLRQDO
5HYLHZ%RDUGIURP 2FWREHUWR6HSWHPEHU 5HYLHZHGE\WKH)XOO%RDUGRQ

&RQVHQWUHTXLUHPHQWV
Â…1RWDSSOLFDEOH
 Â…&)5FZDLYHURIGRFXPH QWDWLRQRIFRQVHQWIRUWKH WHOHSKRQHVFUHHQ 
36LJQDWXUHE\WKHSHUVRQVREWDL QLQJFRQVHQWLVUHTXLUHGWRGRFXPHQWWKHFRQVHQWSURFHVV
Â…'RFXPHQWDWLRQRIDQL QGHSHQGHQWDVVHVVPHQW RIWKHSDUWLFLSDQWÂ¶ VFDSDFLW\WRFRQVHQWLVDOVR
UHTXLUHG
$SSURYHGIRUUHFUXLWPHQWRIVXEMHFWVZKRODFNFDSDFLW\WRFRQVH QW31R <HV 

)LHOG0RQLWRULQJ5HTXLUHPHQWV 35RXWLQH 6SHFLDOBBBBBBBBBBBBBBBBBBB


33 332QO\FRSLHVRIFRQVHQWGRFXPHQWVWKDWDUHFXUUHQWO\DSSURYHG E\WKH,5%PD\EHXVHGWRREWDLQ
FRQVHQWIRUSDUWLFLSDWLRQLQWKLVVWXG\
33 33$SURJUHVVUHSRUWDQGDSSOLFDWL RQIRUFRQWLQXLQJUHYLHZLVUH TXLUHGPRQWKVSULRUWRWKH
H[SLUDWLRQGDWHRI,5%DSSURYDO
33 33&KDQJHVWRWKLVUHVHDUFKPD\QRWEHLQLWLDWHGZLWKRXWWKHUHY LHZDQGDSSURYDORIWKH,5%H[FHSW
ZKHQQHFHVVDU\WRHOLPLQ DWHLPPHGLDWHKD]DUG VWRSDUWLFLSDQWV
33 33$OOVHULRXVDQGRUXQDQWLFLSDWH GSUREOHPVRUHYHQWVLQYROYLQJ ULVNVWRVXEMHFWVRURWKHUVPXVWEH
UHSRUWHGLPPHGLDWHO\WRWKH,5%3 OHDVHUHIHUWRWKH3,,5%ZH EVLWHDWKWWSLUEQ\VSLRUJ IRU
$GYHUVH(YHQW5HSRUWLQJ3URFHGXU HVDQGDGGLWLRQDOUHSRUWLQJUHTXLUHPHQWV


7KLVVWXG\UHTXLUHVD&HUWLILFDW HRI&RQILGHQWLDOLW\3OHDVHIRUZDUGZKHQREWDLQHG

&F 5)0+ &8*UDQWV2IILFH &80&,5%(QFO &)V
(1;[
 
Protocol Summary Form
6850
Levin, [LOCATION_009]s
 
Page 1 of 34  
 Protocol Title:
A Sequenced Behavioral and Medication
Intervention for Cocaine Dependence
 
Protocol Number:
[ADDRESS_474509] Approval:
N/A
 
Expi[INVESTIGATOR_5952]:
Not yet accepted
 Version Date:
10/31/2013
 
 
 
 
 
Clinic:
Substance Treatment And Research Services
(STARS)
 
Principal Investigator:
[INVESTIGATOR_378952], MD
Email: [EMAIL_1019]
Telephone: [PHONE_7844]
 Co-Investigator(s):
Kenneth Carpenter, PHD
 
Research Chief:
Richard Foltin, PHD
 
 
 
Cover Sheet
 
Choose from the following that is applicable to your study
I am submitting a new protocol
 
Division & Personnel
 
Division
 
What Division/Department does the PI [INVESTIGATOR_40348]?
Substance Abuse
Within the division/department, what Center or group are you affiliated with, if any? 
Substance Treatment and Research Service
 
Unaffiliated Personnel
 
List investigators, if any, who will be participating in this protocol but are not affiliated with
[LOCATION_001] State Psychiatric Institute or Columbia University. Provide: Full Name, Degrees
and Affiliation.
none
 
3URWRFRO6X[COMPANY_003]U\)RUP

/HYLQ)UDQFHV
3DJHRI 3URFHGXUHV
7RFUHDWHWKHSURWRFROVX[COMPANY_003]U\IRUPILUVWLQGLFDWHLIWKLVUHV HDUFKZLOOLQFOXGHDQ\RIWKH
IROORZLQJSURFHGXUHV
3V\FKLDWULF$VVHVVPHQW
&ROOHFWLRQRI%LRORJLFDO6SHFLPHQV
0HGLFDWLRQ7ULDO
8VHRI3ODFHERRU6KDP7UHDWPHQW
3V\FKRWKHUDS\7ULDO
0HGLFDWLRQ)UHH3HULRGRU7UHDWPHQW:DVKRXW
$XGLRRU9LGHRWDSLQJ
2IIODEHO8VHRI'UXJRU'HYLFH
,QWHUQHWEDVHG'DWD&ROOHFWLRQRU7UDQVPLVVLRQ
3RSXODWLRQ
,QGLFDWHZKLFKRIWKHIROORZLQJSRSXODWLRQVZLOOEHLQFOXGHGLQWKLVUHVHDUFK
0HGLFDOO\DQG3V\FKLDWULFDOO\+HDOWK\6XEMHFWV
$GXOWV
6XEVWDQFH8VHUV
5HVHDUFK6XSSRUW)XQGLQJ
:LOODQH[LVWLQJLQWHUQDODFFRXQWEHXVHGWRVXSSRUWWKHSURMHF W"
1R
,VWKHSURMHFWH[WHUQDOO\IXQGHGRULVH[WHUQDOIXQGLQJSODQQHG "
<HV6HOHFWWKHQXPEHURIH[WHUQDOVRXUFHVRIIXQGLQJWKDWZLOOEHD SSOLFDEOHWRWKLVVWXG\
)XQGLQJ6RXUFH
,VWKH3,RIWKHJUDQWFRQWUDFWWKHVDPHDVWKH3,RIWKH,5%S URWRFRO"
<HV
6HOHFWRQHRIWKHIROORZLQJ7KHJUDQWFRQWUDFWDSSOLFDWLRQLVDSHQGLQJUHYLHZRUDIXQGLQJGHFLVLRQ6RXUFHRI)XQGLQJ)HGHUDO,QVWLWXWH$JHQF\1,'$*UDQW1DPH$6HTXHQFHG%HKDYLRUDODQG0HGLFDWLRQ,QWHUYHQWLRQIRU&RFDLQH 'HSHQGHQFH
3URWRFRO6X[COMPANY_003]U\)RUP

/HYLQ)UDQFHV
3DJHRI *UDQW1XPEHU
5'$$6HOHFWRQHRIWKHIROORZLQJ6LQJOH6LWH%XVLQHVV2IILFH5)0+'RHVWKHJUDQWFRQWUDFWLQYROYHDVXEFRQWUDFW"<HV6XEFRQWUDFWHG"7R1DPHLQVWLWXWLRQV
&ROXPELD8QLYHUVLW\
6WXG\/RFDWLRQ
,QGLFDWHLIWKHUHVHDUFKLVZLOOEHFRQGXFWHGDWDQ\RIWKHIROORZLQJ
1<63,
7KLVSURWRFROGHVFULEHVUHVHDUFKFRQGXFWHGE\WKH3,DWRWKHUI DFLOLWLHVORFDWLRQV
1R
/D\6X[COMPANY_003]U\RI3URSRVHG5HVHDUFK
/D\6X[COMPANY_003]U\RI3URSRVHG5HVHDUFK
7KLVVWXG\ZLOOWHVWDVHTXHQWLDOWUHDWPHQWVWUDWHJ\LQZKLFKD FRPSXWHUEDVHGEHKDYLRUDO
LQWHUYHQWLRQZLOOEHFRPELQHGZLWKDPHGLFDWLRQWRLQFUHDVHWUHDWPHQWUHVSRQVHDPRQJLQGLYLGXDOVQRWUHVSRQGLQJWRWKHEHKDYLRUDOWUHDWPHQWDORQH:HSODQWRHQ UROOWUHDWPHQWVHHNLQJFRFDLQH
GHSHQGHQWSDUWLFLSDQWVDQGDVNWKHPWRSDUWLFLSDWHLQDFRPSXWHUDVVLVWHGEHKDYLRUDOLQWHUYHQWLRQEDVHGRQWKHFRPPXQLW\UHLQIRUFHPHQWDSSURDFKZLWKFRQWLQJHQF\PDQDJHPHQW&5$&07KRVHZKRIDLOWRDFKLHYHDEVWLQHQFHDIWHUWKHILUVWZHHNVZL OOFRQWLQXHWKHEHKDYLRUDOWUHDWPHQW
&5$&0DQGEHUDQGRPO\DVVLJQHGWRDEHKDYLRUDOWKHUDS\HQK DQFHPHQWVWUDWHJ\WKDWZLOO
LQFOXGHHLWKHUPL[HGDPSKHWDPLQHVDOWVH[WHQGHGUHOHDVH0$6(5 RUSODFHERRYHUDZHHN
WULDO7KH3ULPDU\$LPLVWRWHVWWKHK\SRWKHVLVWKDWDPRQJFRF DLQHGHSHQGHQWSDWLHQWVZKRKDYH
IDLOHGWRUHVSRQGWRDQLQLWLDOWULDORIEHKDYLRUDOWKHUDS\&5 $&0DJUHDWHUSURSRUWLRQRI
LQGLYLGXDOVZLOOEHQHILWIURPWKHFRPELQHGWUHDWPHQWDUP&5$& 00$6(5FRPSDUHGWR
SDWLHQWVLQWKHFRPSDULVRQJURXS&5$&03/$&(%2
%DFNJURXQG6LJQLILFDQFHDQG5DWLRQDOH
 
Protocol Summary Form
6850
Levin, [LOCATION_009]s
 
Page 4 of 34  
 Background, Significance and Rationale
      Cocaine dependence remains a serious public health problem (SAMSHA, 2009) that has not
been adequately addressed by [CONTACT_378970]. Psychosocial treatments can
promote behavior change and constitute the backbone of our intervention efforts. However, a
notable proportion of individuals fail to benefit from these strategies alone. Thus, it is important to
identify those individuals less likely benefit from traditional treatment approaches, uncover the
mechanisms promoting treatment response, and develop strategies to enhance the overall
efficacy of our intervention efforts. 
     Behavioral therapi[INVESTIGATOR_378953] (contingency
management, CM) for abstinence, e.g. the Community Reinforcement Approach (CRA), have
shown the most robust and consistent effects in reducing cocaine use among dependent patients
(Dutra et al., 2008; Higgins et al., 1994). Still, a significant proportion of individuals fail to respond
to CM based interventions alone. Recent trials have suggested that combining CM interventions
with medications that boost mono-amine functioning can enhance treatment response above that
of either treatment alone (Kosten et al., 2003; Moeller et al., 2007; Poling et al., 2006; Schmitz et
al. 2008). Our group, using an innovative imaging and treatment design, has further demonstrated
that deficient dopamine transmission, measured with the PET 11C-raclopride displacement
paradigm, predicts poor response to the Community Reinforcement Approach with CM (Martinez,
Carpenter, et al., 2011). This finding provides a key neurobiological target, suggesting enhancing
behavioral interventions with a pharmacotherapy tailored to enhance dopamine transmission may
provide a useful strategy to help boost treatment response among those individuals least likely to
benefit from behavioral treatments alone.
 Among available medications, stimulants produce the most direct and potent augmentation of
dopamine release. Several studies (Anderson, et al., 2009; Levin, 1998, Mooney et al., 2009),
including a placebo-controlled trial that included mixed amphetamine salts-extended release
(MAS-ER) recently completed at our center (see Significance Section), suggest an agonist
replacement strategy with stimulants is effective for promoting abstinence in cocaine dependence.
The beneficial effect of our medication intervention was most notable among the more severely
dependent patients â€“ a group that had a low placebo response rate and maybe less likely to
respond to a behavioral therapy alone. Taken together, the above findings suggest that stimulant
medication may be a particularly effective strategy for enhancing the efficacy of behavioral
interventions among cocaine dependent patients who have failed to respond to behavioral therapy
alone, a group we have demonstrated to evidence dopamine transmission deficits. 
      In light of the above findings, this proposal will be one of the first investigations to employ a
sequential and integrative treatment strategy in which a medication targeting dopamine release
will be used to enhance the efficacy of a behavioral intervention among individuals not responding
to the behavioral treatment alone. We propose a Stage 2 treatment development trial (Behavioral
and Integrative Treatment Development Program, PA-10-012) in which 155 treatment-seeking
cocaine dependent participants will enter behavioral therapy based on the Community
Reinforcement Approach (CRA + CM). Those who fail to achieve sustained abstinence after the
first 4 weeks will continue with the behavioral treatment (CRA + CM) and be randomly assigned to
receive either mixed amphetamine salts-extended release (MAS-ER) or placebo, over a 10-week
double-blind trial. 
      Two features of this trial are designed to improve the ultimate potential for widespread
adoption of this enhanced treatment strategy. First, the trial will use a web-based,
 
Protocol Summary Form
6850
Levin, [LOCATION_009]s
 
Page 5 of 34  
 computer-delivered version of CRA+CM, the Therapeutic Education System (TES). TES has been
shown in an initial trial to be equally effective as therapi[INVESTIGATOR_378954]
(Bickel et al., 2008). Computer delivered interventions such as TES have the potential to
circumvent significant barriers to the adoption of evidence-based practices into community-based
treatments (Bickel et al., 2008; Carroll et al. 2008). Second, this trial tests a sequential treatment
strategy whereby [CONTACT_378971], and those
who fail to respond are treated with a combined behavior therapy and medication strategy. This
personally targeted approach will help guide a more judicial use of medications and the medical
personnel needed to deliver them by [CONTACT_378972].
 
Specific Aims and Hypotheses
 
Specific Aims and Hypotheses
This proposal will be one of the first investigations to employ a sequential and integrative
treatment strategy in which a medication targeting dopamine release will be used to enhance the
efficacy of a behavioral intervention among individuals not responding to the behavioral treatment
alone. We propose a Stage 2 treatment development trial in which 155 treatment-seeking cocaine
dependent participants will enter behavioral therapy based on the Community Reinforcement
Approach (CRA + CM). Those who fail to achieve sustained abstinence after the first 4 weeks will
continue with the behavioral treatment (CRA + CM) and be randomly assigned to receive either
mixed amphetamine salts-extended release (MAS-ER) or placebo, over a 10-week double-blind
trial. 
 
The Primary Aim is to test the following hypothesis 
 
Among cocaine dependent patients who have failed to respond to an initial trial of behavioral
therapy (CRA + CM), a greater proportion in the enhanced behavioral treatment condition
(CRA+CM/MAS-ER) will achieve 3-weeks or more of continued abstinence compared to patients
treated with CRA+CM/PLACEBO. 
 
We will also investigate cognitive and behavioral predictors of response to the behavioral therapy
alone and the effect of medication enhancement on other indicators of treatment response: urine
confirmed weekly cocaine use, craving, quality of life, and treatment retention. Potential
moderators and mediators of an enhanced behavioral treatment effect, including cognitive
functioning, the use of relapse prevention skills, and changes in patient commitment language will
be tested.
 
Description of Subject Population
 
 
Sample #[ADDRESS_474510] population
18-60
 
Gender and Ethnic Breakdown
 
Males (total n=116):       Hispanic  n=35;  Non-Hispanic n =81 
Females (total n=39):      Hispanic  n=12;  Non-Hispanic n= 27
 
American Indian:  n=0
Asian: n=6    (Males=5; Females=1)
Native Hawaiian: n=0
African American: n=79  (Males=59; Females=20)
White: n=70  (Males=52;  Females=18)
 
Description of subject population
We plan to enroll 155 adult participants who are actively using cocaine (evidenced by [CONTACT_378973]), are currently seeking treatment for their drug use and who meet eligibility
criteria.
 
Recruitment Procedures
 
Describe settings where recruitment will occur
The Substance Treatment and Research Service (STARS) is will be the primary facility in which
recruitment will occur. STARS is based at two locations in [LOCATION_001] City. Our uptown clinic is
adjacent to the Presby[CONTACT_24021][INVESTIGATOR_307], a large tertiary care center, which also is the main primary
care provider for the local inner-city neighborhoods of upper Harlem, Washington Heights, and
Inwood. We also have a large suite of treatment offices in Midtown Manhattan ([ADDRESS_474511],
14th Floor) that has offered a more convenient location for participants traveling from NJ and the
 
Protocol Summary Form
6850
Levin, [LOCATION_009]s
 
Page 7 of 34  
 outer boroughs of [LOCATION_001] City (Brooklyn, Queens, and Staten Island).
How and by [CONTACT_40402]/or recruited? 
     Prospective participants will have contact[CONTACT_378974] a screening
appointment. They will be asked to participate in a one-week uniform screening procedure that
includes an evaluation by a Masters or Ph.D. level psychologist and a psychiatrist with a standard
battery of measures including the Mini-International Neuropsychiatric Interview for DSM-IV
disorders. These screening procedures will be covered by [CONTACT_378975] #6582R (PI: [INVESTIGATOR_378955], MD). Potential
participants receive a brief telephone screening and those who are seeking outpatient treatment,
meet no obvious exclusion criteria, and are willing to consider participation in research are
scheduled for screening. The screening process takes place in one to two visits over a one-week
period. During the screening process participants are interviewed by a clinical psychologist or
certified social worker, and receive a medical and psychiatric evaluation by [CONTACT_360178], who
makes the final determination of eligibility after reviewing all aspects of the baseline evaluation.
Individuals who are not eligible or do not wish to participate in research treatment are offered
referrals to other treatment programs in the community
How will the study be advertised/publicized? 
We will recruit individuals with cocaine dependence through newspapers, radio and public service
announcements coordinated by [CONTACT_40422] [INVESTIGATOR_378956]. This method has proven
successful in several clinical trials at STARS. All advertisements will be sent to the Institutional
Review Board for approval. The first phase of recruitment is a structured telephone interview when
the initial contact [CONTACT_58661]. Individuals interested in receiving treatment for cocaine dependence
will be asked to come to STARS for additional screening as per protocol #6582R. Those patients
who meet criteria for cocaine dependence and all other inclusion/exclusion criteria will be asked if
they are interested in participating in the study.
Do you have ads/recruitment material requiring review at this time? 
No
Does this study involve a clinical trial?
Yes
YOU MUST REGISTER AT ClinicalTrials.gov  IMMEDIATELY UPON RECEIPT OF IRB
APPROVAL AND PRIOR TO ENROLLMENT  OF THE FIRST SUBJECT. YOU WILL BE
PROVIDED WITH A NCT REGISTRATION NUMBER ON REGISTRATION. PLEASE REVISE
THIS SECTION OF THE PROTOCOL SUMMARY FORM TO INCLUDE THE NCT NUMBER
AND RE-SUBMIT AS AN AMENDMENT TO THE IRB.
 
Concurrent Research Studies
 
Will subjects in this study participate in or be recruited from other studies? 
Yes
Describe concurrent research involvement
Protocol # 6582R: Evaluation of Potential Substance Abuse Research Participants
Principal Investigator: [INVESTIGATOR_378955], M.D.
 
Screening for this study will be covered by [CONTACT_378976]
6850
Levin, [LOCATION_009]s
 
Page 8 of 34  
 (STARS) umbrella screening protocol #6582R (PI: [INVESTIGATOR_378955], MD). Trained research assistants
and administrative assistants under the supervision of the principal investigator [INVESTIGATOR_378957]. Under protocol #6582R, patients who contact [CONTACT_378977] a personal nature and asked to
provide verbal consent for such questions. A "phone screen" form is completed by [CONTACT_378978], which asks basic demographic information, contact [CONTACT_3031] (for scheduling
purposes) and description of substance use to determine whether an in-person evaluation
appointment is appropriate. Individuals are also informed that if they make an initial screening
appointment this â€œphone screenâ€ information will be forwarded to the clinician to facilitate the first
meeting.
 
Inclusion/Exclusion Criteria
 
Name [CONTACT_40443]/sub sample
Cocaine Dependent Treatment Seekers
Create or insert table to describe the inclusion criteria and methods to ascertain them
 Inclusion Criteria:                                                                             Ascertainment       
   
1) Meets DSM-V criteria for cocaine use disorder             1).  MINI                           
 
2) Used cocaine at least four days in the past month,               2).  Self report; urine drug screen
     use in the past week.
3) Age 18-60.                                                                       3). demographic information
 
4) Able to give informed consent and comply                         4). initial contact [CONTACT_378979]. 
 
 
Create or insert table to describe the exclusion criteria and methods to ascertain them
Exclusion Criteria                                                                            
 Ascertainment
 
 
1) Meets  DSM-V criteria for bipolar disorder,                          1) MINI assessment
 schizophrenia or any psychotic disorder                                  DSM-V diagnostic algorithm.
 other than transient psychosis due to drug abuse.
 
 
Protocol Summary Form
6850
Levin, [LOCATION_009]s
 
Page 9 of 34  
  
2) Participants with MDD, with symptom severity that           2) MINI, HAM-D
    exceeds a HAM-D score of 20, and/or any other               Psychiatric Interview
    current Axis I psychiatric disorder as defined by [CONTACT_2681]-V
    supported by [CONTACT_378980]'s judgment
    are unstable, would be disrupted by [CONTACT_160844],
    or are likely to require specialized pharmacotherapy
 
    or psychotherapy during the study period.
 
3) History of seizures, unexplained loss of consciousness,            3) Medical History
    or traumatic brain injury. 
 
4) History of allergic reaction to candidate medication                  4) Medical History
    (amphetamine).
 
5) Significant current suicidal risk.                                               5) MINI;
psychiatric evaluation
 
6) Pregnancy, lactation, or failure in sexually active                       6) Self-report, serum
HCG
    female patients to use adequate contraceptive methods.
 
7) Unstable physical disorders which might make participation        7) Medical history including
 
Protocol Summary Form
6850
Levin, [LOCATION_009]s
 
Page 10 of 34  
     hazardous such as uncontrolled hypertension, acute hepatitis,          Cardiovascular risk
profile, ECG
    uncontrolled diabetes.
 
8) Elevated transaminase levels (> 3x the normal limit).                   8) Medical History;
Laboratory tests
 
9) Coronary vascular disease                                                         9)  Medical History ECG
    
10) History of failure to respond to a previous adequate               10)  Self-report
      trial of the candidate medication. 
 
11) Current physiological dependence on any other substance       11) MINI; Medical History
      other than nicotine or cannabis that would require a                           Psychiatric
Interview
      medically supervised detoxification. 
 
12) Currently being prescribed psychotropic medication                12) Self-report; Psychiatric
Interview 
       by [CONTACT_20427].
 
13) Are legally mandated (e.g. to avoid incarceration,                   13)  Self-report
       monetary or other penalties, etc.) to participate in 
       substance abuse treatment program.
 
3URWRFRO6X[COMPANY_003]U\)RUP

/HYLQ)UDQFHV
3DJHRI %RG\0DVV,QGH[%0,NJP:HLJKWDQGKHLJKW
PHDVXUHPHQW
:DLYHURI&RQVHQW$XWKRUL]DWLRQ
,QGLFDWHLI\RXDUHUHTXHVWLQJDQ\RIWKHIROORZLQJFRQVHQWZDL YHUV
:DLYHURIFRQVHQWIRUXVHRIUHFRUGVWKDWLQFOXGHSURWHFWHGKHD OWKLQIRUPDWLRQD+,3$$
ZDLYHURI$XWKRUL]DWLRQ1R:DLYHURUDOWHUDWLRQRIFRQVHQW1R:DLYHURIGRFXPHQWDWLRQRIFRQVHQW1R:DLYHURISDUHQWDOFRQVHQW1R
&RQVHQW3URFHGXUHV
,VHOLJLELOLW\VFUHHQLQJIRUWKLVVWXG\FRQGXFWHGXQGHUDGLIIHUHQW,5%SURWRFRO"<HV,QGLFDWH1<63,,5%5'HVFULEH6WXG\&RQVHQW3URFHGXUHV
6FUHHQLQJIRUWKLVVWXG\ZLOOEHFRYHUHGE\WKH6XEVWDQFH7UHDWPHQWDQG5HVHDUFK6HUYLFH
67$56XPEUHOODVFUHHQLQJSURWRFRO53,-RKQ0DULDQL0'7UDLQHGUHVHDUFKDVVLVWDQWVDQGDGPLQLVWUDWLYHDVVLVWDQWVXQGHUWKHVXSHUYLVLRQRIWKHSULQFLSDOLQYHVWLJDWRUFRQGXFWWKHLQLWLDOSKRQHVFUHHQLQJ8QGHUSURWRFRO5SDWLHQWVZKRFRQWDFW67$56LQWHUHVWHGLQUHVHDUFKWULDOSDUWLFLSDWLRQDUHLQIRUPHGWKDWWKH\ZLOOEHDVNHGTXHVWLRQVRIDSHUVRQDOQDWXUHDQGDVNHGWRSURYLGHYHUEDOFRQVHQWIRUVXFKTXHVWLRQV$SKRQHVFUHHQIRUPLVFRPSOHWHGE\WKHSKRQHVFUHHQHUZKLFKDVNVEDVLFGHPRJUDSKLFLQIRUPDWLRQFRQWDFWLQIRUPDWLRQIRUVFKHGXOLQJSXUSRVHVDQGGHVFULSWLRQRIVXEVWDQFHXVHWRGHWHUPLQHZKHWKHUDQLQSHUVRQHYDOXDWLRQDSSRLQWPHQWLVDSSURSULDWH,QGLYLGXDOVDUHDOVRLQIRUPHGWKDWLIWKH\PDNHDQLQLWLDOVFUHHQLQJDSSRLQWPHQWWKLVÂ³SKRQHVFUHHQÂ´LQIRUPDWLRQZLOOEHIRUZDUGHGWRWKHFOLQLFLDQWRIDFLOLWDWHWKHILUVWPHHWLQJ
,QGLFDWHZKLFKRIWKHIROORZLQJDUHHPSOR\HGDVDSDUWRIVFUHHQLQJRUPDLQVWXG\FRQVHQW
SURFHGXUHV
&RQVHQW)RUP
3HUVRQVGHVLJQDWHGWRGLVFXVVDQGGRFXPHQWFRQVHQW
6HOHFWWKHQDPHVRISHUVRQVGHVLJQDWHGWRREWDLQFRQVHQWDVVHQW
 
Protocol Summary Form
6850
Levin, [LOCATION_009]s
 
Page 12 of 34  
 Bisaga, Adam, MD
Bryan, Benjamin, MD
Dakwar, Elias, MD
Evans, Elizabeth
Kelly, Meredith, MD
Levin, [LOCATION_009]s, MD
Mariani, John, MD
Notzon, Daniel
Shakibaie Smith, Shabnam, MD
Vaughan, Barney, MD
Type in the name(s) not found in the above list
  Sullivan, Maria, MD
 
Study Procedures
 
Describe the procedures required for this study
 Personnel:
 
[LOCATION_009]s R. Levin, M.D.: Psychiatrist with 22 years of experience in substance abuse treatment will
assume scientific responsibility for all aspects of this protocol, including supervising all staff
members responsible for recruitment of patients, clinical care, and collection and analysis of the
data, and manuscript writing.
 
Kenneth Carpenter, Ph.D.: Psychologist with [ADDRESS_474512]: ([LOCATION_009]s Levin, M.D., Maria Sullivan, M.D., Ph.D., Adam Bisaga, M.D.,
John Mariani, M.D., Shabnam Shakibaie, M.D., Benjamin Bryan, M.D., Elias Dakwar, M.D.,
Meredith Kelly, M.D., Elizabeth Evans M.D., Daniel Notzon M.D.,  and Barney Vaughan, M.D.).
The Research Psychiatrist will meet with individuals who meet the initial criteria for cocaine
dependence to determine if they may be eligible for the treatment study. S/he will evaluate the
patient's eligibility for study entry. After individuals are determined to be eligible for the study
based on all inclusion and exclusion criteria, the research psychiatrist will describe the study to the
patient and obtain informed consent after s/he has answered all questions related to the study
procedures. If the patient enters the treatment study, the research psychiatrist will meet with the
patient each week to conduct the research assessments (i.e. Clinical Global Impression and the
Cocaine Selective Severity Assessment), and assess and manage side effects. The research
psychiatrist will be responsible for the overall clinical care, consultation and coordination of care
with the clinical and research staff.
 
Interviewer/Therapi[INVESTIGATOR_541]: (Elisa Leimsider, M.S.W., Kenneth Carpenter, Ph.D., Amy Mahony, M.A.,
 
Protocol Summary Form
6850
Levin, [LOCATION_009]s
 
Page 13 of 34  
 Margaret Rombone, Ph.D., Jaclyn Bronstein, M.A., Paula Bertone, M.A., and Jack Grabon,
M.S.W.) has a doctorate in clinical psychology, a masterâ€™s degree in clinical psychology, or a
masterâ€™s degree in social work. S/he will be involved in conducting all interviews and assessments
to ensure consistent diagnoses of substance use disorders. S/he will also be involved in patient
recruitment. 
 
Research Nurse (Marcia Loughran, R.N., M.S.N.): The research nurse will see patients enrolled in
the treatment study three times a week to obtain vital signs, monitor side effects, and collect blood
samples. Additional responsibilities of the research nurse will include sending all biological
samples to the correct laboratories and ensuring accurate records of routine blood work and
medical information. 
 
Research Assistant (Arielle Radin, B.A.): has a Bachelorâ€™s degree in psychology and will be
primarily involved in study management and coordination between the various sites. The research
assistants will conduct telephone interviews and will be involved in recruiting.
 
a. Screening Interviews  will be carried out by 1) therapi[INVESTIGATOR_11437] (Elisa Leimsider, M.S.W., Amy Mahony,
M.A., Margaret Rombone, Ph.D., Jaclyn Bronstein, M.A., Paula Bertone, M.A., Jack Grabon,
M.S.W. who have a doctorate in clinical psychology, a masterâ€™s degree in clinical psychology, or a
masterâ€™s degree in social work) trained by [INVESTIGATOR_124]. Carpenter and 2) Psychiatrist/Physicians (Drs.
Levin, Bisaga, Mariani, Shakibaie, Sullivan, Bryan, Dakwar, Kelly, and Vaughan), who have
extensive experience with individuals with substance use disorders in treatment settings.
 
b. Drug Administration:  Extended-release mixed amphetamine salts (MAS-ER), and matching
placebo will be provided by [CONTACT_378981]. Doses and dose schedule are
described below. Physiological effects (heart rate and blood pressure) and side effects will be
monitored three times a week. The research psychiatrist (Drs. Bisaga, Mariani, Shakibaie,
Sullivan, Bryan, Dakwar, Huynh, Kelly, Evans, Notzon and Vaughan) will determine medication
dose adjustments with consultation from the Principal Investigator ([CONTACT_21145]). Consultations with
[CONTACT_21145] will take place at a weekly meeting with the research psychiatrists where all patients
enrolled in the study will be discussed. [CONTACT_21145] will also be available to the research psychiatrists
by [CONTACT_378982] a more immediate consultation about a patientâ€™s medication dose is
needed.
 
c. Behavioral assessments will be carried out by [CONTACT_138207]/therapi[INVESTIGATOR_11437] (Elisa Leimsider,
M.S.W., Amy Mahony, M.A., Margaret Rombone, Ph.D., Jaclyn Bronstein, M.A., Paula Bertone,
M.A., Jack Grabon, M.S.W.) under the supervision of [CONTACT_212893]. 
 
d. Computer-assisted Behavioral Therapy . Monitoring and discussion of the computer delivered
copi[INVESTIGATOR_378958]/therapi[INVESTIGATOR_11437] (Elisa
Leimsider, M.S.W., Amy Mahony, M.A., Margaret Rombone, Ph.D., Jaclyn Bronstein, M.A., Paula
Bertone, M.A., Jack Grabon, M.S.W.) under the supervision of [CONTACT_212893]. 
 
General Design:
 155 subjects whom meet criteria for cocaine dependence, and all other study inclusion and
 
Protocol Summary Form
6850
Levin, [LOCATION_009]s
 
Page 14 of 34  
 exclusion criteria (described above) will begin a 4-week computer-assisted behavioral intervention.
Those participants not responding to the behavioral intervention will begin a 10-week double-blind,
placebo-controlled treatment trial. Subjects will be randomized to receive either placebo or
MAS-ER. Table [ADDRESS_474513] of augmenting a self-directed version of the Community
Reinforcement Approach (CRA; Budney & Higgins, 1998) with Mixed Amphetamine
Salts-Extended Release (MAS-ER) to improve treatment response among cocaine dependent
patients who do not benefit from the behavioral intervention alone. Patients who do not respond by
[CONTACT_378983]+CM intervention will be randomized to a 10-week double blind design to
test the combined effects of CRA+CM/MAS-ER against a CRA+CM/PLACEBO control condition.
Participants who are randomized to the combination behavioral treatment and medication arm
(CRA+CM/MAS-ER) will have their dose titrated to 60 mg MAS-ER daily (over 2 weeks) and
maintained on this dose through week 13 of the trial. During week 15, participants will be tapered
off the medication (see Table 1. below). Patients responding to the CRA+CM intervention in the
first four weeks of treatment will continue with the behavioral intervention and be assessed in
parallel to the two (CRA+CM/MAS-ER and CRA+CM/PLACEBO) enhanced treatment arms. 
 
Randomization : Those patients randomized to the placebo group will continue to receive
CRA+CM and placebo throughout the treatment. Patients randomized to the CRA+CM/MAS-ER
group will begin receiving medication at the start of week 5 and will receive a stable dose of
MAS-ER by [CONTACT_95839] 7.
 
Dosing Schedule: Subjects will take capsules (PBO or MAS-ER) as titrated in Table 2 below. 
 
 
Medication Lead-out : During week [ADDRESS_474514] systematic observation of effects of medication
discontinuation.
 
27 Week Outcome : Twelve weeks after study completion (27 weeks after enrollment) an attempt
will be made to evaluate all participants to explore whether there may be effects of treatment that
endure or emerge after medication discontinuation. In exploratory analyses, outcome at 27 weeks
will be compared among three groups: those originally assigned to continue behavioral therapy
alone, patients assigned to receive either medication or placebo. Group comparisons will be
conducted on the main primary and secondary outcomes. 
 
Medication : MAS-ER, and matching placebo will be prepared by [CONTACT_378984],
 
Protocol Summary Form
[ADDRESS_474515] orders the dose of double-blind medication for the coming
week according to the schedule (shown in Table 2). The psychiatrist will adjust the dose according
to tolerability. MAS-ER or matching placebo will be given in a fixed-flexible dose schedule with the
MAS-ER dose titrated to 60 mg per day. 
 
MAS-ER or matching placebo will be taken once per day in the morning or early afternoon since it
may be activating. The medication will be packaged in gelatin capsules with lactose filler plus 25
mg of riboflavin. MAS-ER or matching placebo are given in a â€œfixed-flexible" dose schedule with
the dose titrated to [ADDRESS_474516] 20 mg/day of MAS-ER
the medication will be discontinued. Patients will be encouraged to set a quit date three weeks
after starting study medications (the end of the titration phase of MAS-ER). During week 14
patients on active medication will be tapered off MAS-ER.  
 
Planned/unplanned absences that would require the patient to be given more than one week
worth of medications will be considered on a case-by-case basis. In the case of unplanned
absences, up to one week of medication can be shipped via FedEx with signature [CONTACT_379005].
This will allow patients who miss their scheduled appointments to remain on stable medication. 
 
We will evaluate the adequacy of the double-blind by [CONTACT_378985]. The blinded nurse will also be asked to report which drug s/he thinks
each patient is taking. The research staff (i.e., therapi[INVESTIGATOR_541], nurse, research assistant and
psychiatrist) that administers medications and/or conducts interviews and assessments will be
blind to medication condition, urine toxicology results, and medication blood levels during the
course of the 10-week trial. The non-blinded pharmacist will be the only ones who have access to
this information during the trial. However, a sealed envelope will be kept in a locked office if the
Principal Investigator [INVESTIGATOR_378959]. At the completion of the
10-week trial, or at the conclusion of the patientâ€™s involvement in the trial (if they do not complete
all 10 weeks), patients will learn their treatment assignment.
 
 
Computer-assisted CRA with Contingency Management:  All consented patients will begin the trial
receiving CRA+CM delivered in a computer-assisted treatment format. Patients will be asked to
attend the clinic 3 times per week for urine toxicology, and on 2 of those occasions, participate in a
30-40 minute session using the self-directed version of the Community Reinforcement Approach
(CRA+CM). CRA+CM is a well-established skills oriented treatment for cocaine dependence that
utilizes tangible incentives to promote abstinence (Budney & Higgins, 1998). This treatment has
 
Protocol Summary Form
6850
Levin, [LOCATION_009]s
 
Page 16 of 34  
 been utilized in other studies in our clinic (Martinez, Carpenter et al., 2011; Carpenter et al., 2008).
The Therapeutic Education System (TES), an empi[INVESTIGATOR_378960] (Bickel,
Marsch, et al., 2008), is delivered via effective informational and multimedia technologies, includes
32 core interactive, multimedia modules, beginning with basic cognitive behavioral relapse
prevention skills (e.g. drug refusal skills) and moving on to improving psychosocial functioning,
(e.g. employment status, social relations) and HIV risk reduction. All TES sessions will occur in a
private office equipped with a PC and headphones; with clinical staff in close proximity to ensure
compliance and clinical support. 
 
 
TES is self-directed and includes a training module to teach individuals how to use it. All text is
accompanied by [CONTACT_378986] (e.g. personalized functional analysis) and a variety of interactive exercises to
better enhance learning (e.g., graphics). TES is designed to address substance use in general
and is inherently flexible, addressing the substance use-related problems with which individuals
may present. All patients will work through the modules in a standard sequential order. The
â€œfluency-basedâ€ Computer-Assisted Instruction (CAI) will continually assess a participantâ€™s grasp
of the material and adjust the pacing and level of repetition of skills to promote mastery of the
information being introduced. The electronic reporting system will allow counselors to view
summaries of the participantâ€™s progress. Every other week (bi-weekly) individuals will meet with
their counselor (on visit three of those weeks) for approximately 30 minutes to review their
progress in treatment and revise the sequence of treatment modules if warranted.
 
 
Contingency Management Procedures : The CM component will follow the efficacious prize-based
incentive procedures employed in other community based drug treatment studies (Petry et al.,
2004; 2005), that reduce cocaine use and offset the cost of high magnitude vouchers. Patients
receive draws from a prize bowl for each urine testing negative for benzoylecgonine. Failure to
submit a scheduled specimen will be treated as cocaine positive. Each draw has a probabilistic
chance of yielding one of four outcomes: an encouraging statement (e.g. â€˜good jobâ€™), a small prize
valued at $2.50, a large prize valued at $20, or a jumbo prize valued at $100. The probability for
each particular outcome is fixed for every draw and is based on the relative number of slips for
each prize category in the prize bowl. Using Petry et alâ€™s (2005) framework, each prize bowl will
have 500 prize slips. 250 slips will be the encouraging statement (50% of the total slips), 209 slips
will be for small prizes (41.8%), 40 slips will be for large prizes (8%), and 10 slips will be the jumbo
prize (0.2%). Patients will earn 1 draw for every week in which all urines are benzoylecgonine
negative, thus employing the escalating incentive structure employed in other CM based
treatments (Higgins et al., 1993; Petry et al., 2005). The escalating schedule will increase to a
maximum of 10 draws. Consistent with Petry et al.â€™s (2005) prize bowl procedure, a single large
prize will be awarded when a participant first achieves 2 weeks of abstinence to offset the low rate
of reinforcement (low number of draws) during the beginning of the program. Abstinence from
cocaine is confirmed by [INVESTIGATOR_2394]-site urine testing (Abuscreen On-Trak system, [COMPANY_002] Diagnostics).
 
Protocol Summary Form
6850
Levin, [LOCATION_009]s
 
Page 17 of 34  
 Patients are given immediate feedback on the toxicology results and are updated on the amount
of draws earned to that point in time. A participant never loses the prizes earned. 
 
 
Audiotapi[INVESTIGATOR_378961]: Counseling sessions will be digitally recorded for purposes
of supervision, treatment fidelity, and for the psycholinguistic coding of sessions at Baseline and
Week 5. Participants will be asked to consent for the audiotapi[INVESTIGATOR_378962]. All
digital files will be stored on a secure computer dedicated for that purpose alone. The computer
will not be connected to the internet. 
  
Assessment of Side Effects and Medication Compliance : The research nurse and psychiatrist will
query about side effects related to the study medication. Reported side effects and other treatment
emergent events since the past visit will be recorded; additionally, the severity of the side
effect/treatment emergent event, the action taken, and the continuation or resolution of the side
effect/treatment emergent event will be documented. 
a) Ongoing medical assessments. At each visit, the research nurse will monitor vital signs (heart
rate and blood pressure) and inquire about medication-related side effects. Inability to tolerate
medication side effects will result in the reduction or temporary discontinuation of study
medications.  Blood pressure and heart rate assessments that indicate SBP>140, DBP>90, sitting
quietly HR>100 for two consecutive weeks will result in the discontinuation of study medications. 
Vital signs assessments indicating SBP>160, DBP>110, sitting quietly HR>[ADDRESS_474517] Questionnaire
consists of 2 parts: 1) self-reported side effects obtained by [CONTACT_378987] 2)
a checklist of symptoms rated from absent to severe, incorporating the major organ systems (e.g.,
gastrointestinal, neurological, cardiovascular). Patients may be removed from the study if they
repeatedly miss study visits. 
 
The research psychiatrist will meet with the patient once a week. At each weekly visit, s/he will
discuss side effects of medication, review the Side Effect Questionnaire, will evaluate all reported
vital signs and review cardiac risks to determine whether the dose is being tolerated, and assess
substance use trends for clinical worsening. Cardiac risks will be documented in a structured
progress note. If blood pressure and heart rate are consistently above cut-off levels as described
above then the medication dose will be lowered or discontinued. If clinically indicated (e.g., side
effects are not tolerable, chest pains, fainting, arrhythmias), the research psychiatrist will
discontinue the medication. 
You can upload charts or diagrams if any
Table 1 PSF.pdf
Table 2 PSF.pdf
 
Criteria for Early Discontinuation  
 
Protocol Summary Form
6850
Levin, [LOCATION_009]s
 
Page 18 of 34  
  
Criteria for Early Discontinuation
 
 
Removal from the Study for Worsening of Substance Abuse:  Participants whose substance abuse
significantly worsens during the course of treatment will be removed and treated clinically. If
necessary, a referral for inpatient treatment will be made. This involves clinical judgement on the
part of the treating psychiatrist(s) who are experienced with this population. This does not include
transient modest worsening of drug use since substance dependence is a chronic relapsing
condition. If more intensive treatment is deemed necessary, the participant will be offered
continued weekly meetings with the physician and their counselor until appropriate referral can be
made. 
 
Drop-out criteria during the screening and study period include:
 
1) If the patient develops serious psychiatric symptomatology (weekly psychiatric evaluation, CGI
> 6 (much worse than baseline) for two consecutive weeks).
 
2) If the patient develops signs of cardiovascular instability (weekly vital signs and clinical
evaluation; pulse at rest > [ADDRESS_474518] > 140/90 mm Hg for more than 2 weeks or SBP >
160, DBP > 110, sitting quietly HR >110 on any visit will result in immediate discontinuation of
study medication).
 
3) Cardiac risks defined as chest pains, fainting, or arrhythmias.
 
4) If the patient's continued cocaine use even if improved from baseline, places them at risk for
self-destructive behavior or otherwise places them at significant risk (weekly clinical evaluation;
CGI > 6 (much worse than baseline) for two consecutive weeks).
 
5) If the patient becomes pregnant (monthly urine pregnancy testing). 
 
 
Protocol Summary Form
6850
Levin, [LOCATION_009]s
 
Page 19 of 34  
  
 
 
Blood and other Biological Samples
 
Please create or insert a table describing the proposed collection of blood or other
biological specimens
Approximately 20 ml of blood (4 teaspoons) will be drawn at the time of baseline assessment and
study completion for routine analyses (hematology, blood chemistry (including liver function tests),
TSH, and blood pregnancy test for women). They may be repeated during the study if clinically
indicated.  
 
Quantitative urine toxicology screens conducted at each visit (3 per week) will provide
benzyolecgonine levels and serve as an objective marker of current cocaine use. 
 
HIV testing will be offered in order to determine the HIV status of all possible participants;
participants may refuse if they do not want to be tested. Nursing staff will provide Pre and
Post-test counselling to assist participants with any HIV+ results. Pre-HIV test counselling
discusses the possibilities of a HIV+ test and the procedures after a positive HIV test is found.
Post-HIV counselling assesses for suicidal and/or homicidal ideation, along with domestic violence
issues. If a person tests positive for HIV, the research psychiatrist on staff with be notified and will
do a secondary evaluation for necessity of immediate psychiatric care. Additionally the nursing
staff will notify the department of health and provide a list of referrals for follow-up care.
 
A confirmatory HIV test will not routinely be done due to the accuracy of the saliva quick test,
however if a participant tests positive using the saliva quick test a confirmatory blood test will
immediately be done.
 
Assessment Instruments
 
Create a table or give a brief description of the instruments that will be used for
assessment
Screening:
 
Psychiatric and substance use information will be obtained in the structured screening interview.
The following evaluations will be used to determine whether a patient is appropriate for study
participation. These data will be collected during the initial interviews and will cover
inclusion/exclusion criteria. Additionally, a brief description of the study will be provided to eligible
subjects to determine if the subject is interested in participating. If so, then informed consent will
be obtained. Full screening will be completed within 1-[ADDRESS_474519] measures.
 
Protocol Summary Form
6850
Levin, [LOCATION_009]s
 
Page 20 of 34  
  
 
Treatment Study Screening Procedures: 
 
 
An important component of this behavioral therapy development study is to identify cognitive,
verbal, and behavioral mechanisms that predict treatment response.  A range of assessment
instruments have been included to assess the relationship between key constructs within each of
these three domains and treatment outcome. This information may provide a basis for continuing
the development of more effective cognitive-behavioral treatment platforms and targeted
pharmacotherapy strategies. 
 
 
Initial contact [CONTACT_378988] : The initial contact [CONTACT_133557] a brief interview to cover
inclusion/exclusion criteria and a brief description of the study will be given to the patient to
determine if the patient is interested in participating. If the patient is interested then an informed
screening consent will be signed by [CONTACT_378989] a member of the research staff.
 
Medical aspects : Patients will receive a full physical examination and an ECG before admission.
Laboratory tests will include: hematology, blood chemistry (including liver function tests),
urinalysis, and blood pregnancy test for women (45 minutes). Urine will be collected and tested for
substances of abuse, three times a week for the duration of the study.
 
Demographic information:  Patients will complete a Demographic Form, Medical and Psychiatric
History Form, and Family Medical and Psychiatric History Form. These self report forms provide
data on age, race, socioeconomic status, marital status, educational and occupational levels,
significant medical history, and current/history of major psychiatric disorder in the patient and
his/her first degree relatives. Patients will also complete a Locator Form so that they can be
contact[CONTACT_51095]-up (30 minutes).
 
c. Screening and Diagnosis:  Uniform screening procedures will be used. A standardized telephone
interview is followed by [CONTACT_378990]. No identifying
information is recorded until the potential participant completes the study explanation and consent
process; evaluation follows consent using standardized measures. Common, standardized intake
and evaluation training will be conducted for all procedures and instruments. 
 
Eligibility Determination via Physical Examination and Psychiatric Evaluation: Review of history,
physical, and laboratory evaluations and the medical-psychiatric evaluation note lead to final
determination of eligibility. This information will be reviewed by [CONTACT_378991].
 
 
Protocol Summary Form
6850
Levin, [LOCATION_009]s
 
Page 21 of 34  
 Intake Evaluation, Instruments, and Outcome Measures (60 â€“ 75 minutes): The Mini-International
Neuropsychiatric Interview DSM-IV (MINI; Sheehan et al., 1998): The MINI, administered by
[CONTACT_44753] (at least masters level), provides current diagnoses of substance use disorders,
mood and anxiety disorders, and screens for psychotic disorders to assure study eligibility. The
Connerâ€™s Adult ADHD Diagnostic Interview for DSM-IV (CAADID; Epstein et al., 2001) is also
administered to assess for the presence of a DSM-IV ADHD disorder. The CAADID has been
used in large-scale pharmacological trials to diagnose adults with ADHD (Michelson et al., 2003).
Instruments are discussed below: 
 
Clinical Global Impression Scale-Observer (CGI-O)  (5 minutes): This modified CGI (Guy, 1976)
measures global severity of cocaine related problems and improvement from baseline (7 point
likert scale). The psychiatrist will make ratings using all available information to yield treatment
outcome data.
 
Addiction Severity Index-Computerzied version (ASI; 5th Edition 1997- 40 minutes) : This widely
used computer administered version evaluates problem severity in seven problem areas
(McLellan et al., 1992). 
 
Timeline Follow-back (TLFB) Assessment  (30 minutes): The Timeline follow-back method (Sobell
and Sobell 1992) will gather self-reported cocaine use data for each day during the 28 days prior
to the study enrollment and each day during the study period. As part of the TLFB interview,
participants are asked to assign a dollar value to the amount of cocaine used. The TLFB will be
used to corroborate urine toxicology results. Marijuana, alcohol, nicotine, and other drug use
self-report data will also be gathered during the TLFB interview. 
 
Cocaine Selective Severity Assessment (5 minutes):  This clinician-rated questionnaire (Kampman
et al, 2002) evaluates the occurrence and severity of cocaine dependence symptoms and is
reported to predict abstinence in medication trials.
 
Brief Substance Craving Scale (BSCS)  (5 minutes): This 16-item self-rated questionnaire
(Somoza et al., 1999) assesses the frequency, intensity and amount of time spent craving cocaine
and other substances.
 
The Risk Assessment Battery  (10 minutes): This questionnaire will assess research participants
for HIV related risky behaviors (Metzger et al, 1992).
 
Quality of Life, Enjoyment and Satisfaction Questionnaire (QLESQ): (short form- 5 minutes)).
(Endicott et al.,1993). Is a self-administered 16-item questionnaire rating each item from 1 (very
poor) to 5 (very good). 
 
Systematic Assessment for Treatment Emergent Events (SAFTEE) Adverse Event Form : The
research nurse or psychiatrist query the participant and log side effects and other treatment
emergent events during the past week (but will also query participants at each visit), record their
severity, and what action was taken, and whether they are continuing or resolved. 
 
 
Protocol Summary Form
6850
Levin, [LOCATION_009]s
 
Page 22 of 34  
 Implicit Relational Assessment Procedure (IRAP; Barnes-Holmes et al., 2008 â€“ 30 minutes)) . The
IRAP is a computer-based task in which participants are asked to respond quickly and accurately
in ways that may be similar or dissimilar to their established beliefs about cocaine use.
Participants are exposed to two practice blocks and six test blocks. Each block presents the same
12 trials; 6 positive consequences of cocaine use and 6 negative consequences of cocaine use.
Participantsâ€™ reaction time to each item is recorded and used to calculate difference scores
between the positive and negative consequence trials to yield an overall score. 
 
Drug Stroop (15 minutes) . (Carpenter et al., 2006) The drug stroop task requires participants to
respond to the color (blue, red, green, yellow) of a drug related or neutral (non-drug related) word
by [CONTACT_378992] a response pad as quickly and accurately as possible. For
each trial, a fixation-cross appears in the center of the monitor screen for 1000ms and was then
replaced by a colored word. Each word remains on the screen until the participant responds or for
a maximum time period of 6000ms. Two blocks of 50 trials, for a total of 100 words ([ADDRESS_474520] groups), follows [ADDRESS_474521] block
of 50 words. The primary measure is interference from cocaine related words, which is calculated
for each participant by [CONTACT_378993]. Positive values (i.e. slower responding to the
cocaine words) are interpreted as reflecting an attentional bias towards cocaine related stimuli.
 
DARN-C Psycholinguistic Coding System  (30 minutes) Amrhein et al., 2003). [CONTACT_379006]â€™s
DARN-C coding system assesses a participantâ€™s Desire, Ability, Reasons, Need, and Commitment
language as it pertains to changing his/her use of cocaine. A participantâ€™s speech is coded along
two dimensions, frequency and strength. This system has been used to predict treatment
engagement and change over a 12-month period. Audiotaped sessions will be coded by [CONTACT_378994]. No identifying information or specific content from a session is transcribed. Coding
procedures yield a string of numerical codes.
 
Wisconsin Card Sort  (15 minutes), a measure of executive functioning and cognitive flexibility.
 
Relapse Prevention Skills: Copi[INVESTIGATOR_72207] (CSS)  â€“ Brief Version. (4 mins) (Litt et al.,
2005) The CSS is a 23-item questionnaire (originally adapted from the Processes of Change
questionnaire, Prochaska et al., 1988) that assesses copi[INVESTIGATOR_378963]. 
 
The Behavior Rating Inventory of Executive Function  (20 minutes) (Adult Version (BRIEF-A; Rabin
et al., 2006) is a 75-item standardized self-report measure that assesses an individualâ€™s
perception of their self-regulation in their everyday environment. It yields nine reliable subscale
scores reflecting executive functioning (e.g. inhibit, self-monitor) and two broader indices:
Metacognition and Behavioral Regulation. The Behavioral Regulation score is the measure of
interest.
 
Working memory (15 minutes Letter-Number Sequencing, Wechsler, 1997), The letter number
sequencing task will be utlized to assess a participantâ€™s working memory.
3URWRFRO6X[COMPANY_003]U\)RUP

/HYLQ)UDQFHV
3DJHRI 7KHGLVFRXQWLQJRIGHOD\HGUHZDUG V'HOD\HG'LVFRXQW3URJUDP5REOHVHWDO
PLQXWHV
3OHDVHDWWDFKFRSLHVXQOHVVVWDQGDUGLQVWUXPHQWVDUHXVHG7$%/(SGI
2IIODEHODQGLQYHVWLJDWLRQDOXVHRIGUXJVGHYLFHV
&KRRVHIURPWKHIROORZLQJWKDWZLOOEHDSSOLFDEOHWR\RXUVWXG\ 
'UXJ
6HOHFWWKHQXPEHURIGUXJVXVHGLQWKLVVWXG\
'UXJ
1DPHRIWKHGUXJ
([WHQGHGUHOHDVHPL[HGDPSKHWDPLQHVDOW0DQXIDFWXUHUDQGRWKHULQIRUPDWLRQ
2WKHU1DPH$GGHUDOO;5
0DQXIDFWXUHU6KLUHDQG7HYD
$SSURYDO6WDWXV
,1'LVDSSURYHG,1':KRKROGVWKH,1',1'VSRQVRU",1'LVKHOGE\3,&8,QYHVWLJDWRU/HYLQ)UDQFHV0'
5HVHDUFK5HODWHG'HOD\WR7UHDWPHQW
:LOOUHVHDUFKSURFHGXUHVUHVXOWLQDGHOD\WRWUHDWPHQW"<HV0D[LPXPGXUDWLRQRIGHOD\WRDQ\WUHDWPHQW2QFHVFUHHQLQJLVFRPSOHWHGWKHUHLVQRGHOD\IRUVWXG\HQWU\IRUHOLJLEOHSDWLHQWV
 
Protocol Summary Form
[ADDRESS_474522]
been randomized to the active medication arm. Those assigned to the placebo group will not
receive active medication, but will continue to receive the behavioral treatment. CRA+CM is an
evidenced based treatment program for the treatment of cocaine dependence. 
Maximum duration of delay to standard care or treatment of known efficacy
 Because the screening procedure sometimes requires 2-3 meetings, individuals may not begin
the computer-assisted CRA+CM therapy until 2-[ADDRESS_474523] referrals for other treatment options.  
 
Risks/Discomforts/Inconveniences 
 
Risks that could be encountered during the study period
The major risk of research participation is related to drug administration. MAS-ER has been
approved for maximal use of up to 60 mg/day. Adverse events most commonly associated with
amphetamine administration include: insomnia, emotional labiality, nausea/vomiting, nervousness,
palpi[INVESTIGATOR_814], elevated blood pressure, and rapid heart rate. Less common serious side effects
include severe hypertension, seizures, psychosis, and myocardial infarction. The risk of abuse is
of concern with the administration of amphetamine but is substantially lowered by [CONTACT_378995]. Although amphetamines have been prescribed for several
decades and no clear teratogenic risks have been described, it cannot be assumed that it is safe
to administer during pregnancy. Female participants will be required to use adequate methods of
birth control (condom with spermicide, diaphragm with spermicide, birth control pi[INVESTIGATOR_3353]). Serum
pregnancy tests will be evaluated at baseline and throughout the trial.
 
Protocol Summary Form
[ADDRESS_474524] been reported in children taking Adderall. This
concern caused Health Canada to remove Adderall from the market in 2/2005; however, Health
Canada returned Adderall to the Canadian market in 8/2005 because of inconclusive evidence. At
the February 2006 advisory panel meeting it was learned that Adderall was involved in more fatal
case reports than any other ADHD/ADD drug, with 24 deaths reported from 1999 through 2003
regarding patients who took Adderall for ADHD or ADD. The warning information for all stimulant
ADHD drugs includes the following:
 
â€¢ Sudden death has been associated with stimulants at usual doses in children and teens with
structural heart abnormalities or other serious heart problems.
 â€¢ Children, teens, or adults who are being considered for treatment with stimulant medicines
should have a careful checkup (including family history and a physical exam) to check for heart
disease.
 â€¢ Patient who develop symptoms such as chest pain during exertion, unexplained fainting, or
other possible heart symptoms should promptly get a heart evaluation.
 â€¢ Sudden death, stroke, and heart attack have been reported in adults taking stimulant drugs at
usual doses for ADHD.
 Adults with such heart abnormalities should also generally not be treated with stimulant drugs.
 
The reports of sudden unexplained death have been reported in FDA post-marketing surveillance
of Adderall/Adderall XR (that is, reports released after a medication is put on the market). Most of
these cases had complicating factors, including heart disease, family history of a certain kind of
heart disease (ventricular tachycardia), heat exhaustion, dehydration, near drowning, rigorous
exercise and/or unexplained accumulation of the drug resulting in toxic levels. Because of how
rare this problem is, it is not known whether the rate of death in association with Adderall XR
differs statistically from that of the general public (about 1/100,000). The Food and Drug
Administration has been reviewing these cases, and at the present time has not concluded that
Adderall or Adderall XR were responsible for these deaths. The FDA is continuing to investigate
these reports, and has not recommended withdrawal from the market.
 
 
Amphetamines have a high potential for abuse. Taking amphetamines for long periods of time
may lead to drug addiction. Particular attention should be paid to the possibility of people obtaining
amphetamines for non-therapeutic use or distribution to others. The FDA has issued a Black Box
warning regarding the use of Adderall XR and amphetamines. Misuse of amphetamine may cause
sudden death and serious cardiovascular adverse events. 
 
 
In this study, we will protect adults from this risk by [CONTACT_378996]. Adults will receive a physical examination,
electrocardiogram, thyroid function tests and liver function test at baseline. Vital signs will be
 
Protocol Summary Form
[ADDRESS_474525] how much of this medicine
enters into the bloodstream; we will monitor all other medications, including over the counter
medications that the adult may take. Prescription and non-prescription medications will be
monitored by [CONTACT_378997]; any potential drug interactions will be reviewed by a
physician (see also exclusion criteria).
 
Weight loss is also a side effect of MAS-ER. Therefore, BMI will be monitored closely during the
study and dose adjustments will be made if necessary. Side effects can be reduced or eliminated
by [CONTACT_378998].
 
There is a growing literature in which cocaine dependent individuals were maintained on
methylphenidate or dextroamphetamine without untoward events (Grabowski et al., 2001; 2004;
Levin et al., 2005; Schubiner et al., 2001). Although the medication has been well-tolerated when
administered to cocaine-dependent individuals, we cannot be absolutely certain that the side
effect profile will remain the same when co-administered with cocaine. The interactions between
amphetamines, cocaine, or other drugs which participants may use during the study are not
known at this time. Cocaine can cause seizures and serious heart problems, and it is not known
whether amphetamines would alter these risks. Therefore, patients with histories of convulsions or
heart disease will be excluded. Patients will be informed about the common side effects of
MAS-ER and warned about the possibility of interactions between this medication and cocaine or
other drugs. Participants in this study are identified as users of other drugs. To the extent that they
do not reduce or eliminate other drug use, risk may increase. Some of these risks are known;
others are of an uncertain magnitude. Our experience with these issues is discussed below in the
methods to attenuate risk. 
 
Blood drawing may cause slight discomfort at the site of needle entry, resulting in a small bruise.
Participants will be warned about this. Other risks include participantsâ€™ discomfort with being asked
uncomfortable questions or the psychological distress that may occur if a participant agrees to be
tested for HIV. 
 
As one progresses through the treatment study, depressive symptoms may emerge as a result of
subjects using cocaine or being unable to stop using. Depressive symptoms will be monitored
once a month using the Hamilton Depression Scale. 
 
The structured interviews, rating scales, and questionnaires should add no physical risk. The
major disadvantage is the time required to complete them and that some of the questions might be
embarrassing to patients. Our past experience with these measures indicates that they are
acceptable to participants. However, some people have found them uncomfortable and/or tiring
because the interviews/assessments are long and of a personal nature. Patients are informed that
they may refuse to answer any questions and may ask to stop at anytime. If participants become
upset during the interviews/assessments, assistance will be made available to them. 
 
Risks of Diversion  The risks of stimulant diversion are small but not negligent. The SAMHSA
National Survey on Drug Use and Health collects data on a broad array of substances of abuse,
including non-medical use of prescription stimulants. For 2010, nonmedical stimulant use was
 
Protocol Summary Form
6850
Levin, [LOCATION_009]s
 
Page 27 of 34  
 0.4%. While not insignificant, it is substantially lower than nonmedical use of tranquilizers or pain
medication. The risk of abuse is of concern with the administration of amphetamine but is
substantially lowered by [CONTACT_378999]. Nevertheless we will take
several precautions to minimize the risks of abuse and/or diversion of Adderall. Adderall will be
provided on a weekly basis. Patients who are found to abuse/divert their study medication will be
taken off their study medication.
Describe procedures for minimizing risks
 
 
Exclusion Criteria
 
The exclusion criteria (see above) are designed to minimize the medical and psychiatric risks to
participants as discussed above, including risks of adverse events and side effects such as
intoxication. Pregnant or lactating women or those not practicing reliable birth control methods are
excluded. Patients are instructed to inform their psychiatrist immediately if they suspect they may
be pregnant, and urine HCG is monitored monthly during the trial. 
Patients with histories of psychotic illness other than transient drug-related psychosis that in the
investigatorâ€™s judgment are unstable or would be disrupted by [CONTACT_379000].
During the study, [CONTACT_21145] and the clinic staff will coordinate clinical care. Additionally, the treating
psychiatrist monitors participantsâ€™ mental status weekly. 
 
The baseline medical evaluation includes physical examination, blood chemistry profile (including
liver function tests, complete blood count, urinalysis, HCG) and electrocardiogram (ECG) is
designed along with clinical history to detect chronic and unstable medical illnesses. 
 
 
History of allergic or adverse reactions to MAS-ER is exclusionary. 
 
 
Participants with significant suicide risk at the time of initial evaluation or history of serious suicide
attempt will be excluded and referred for appropriate non-research treatment. Participants will be
examined for suicidal ideation and risk during their weekly visits with the research psychiatrist and
participants who develop a significant risk during the trial will be removed from the study and
treated as clinically indicated.
 
 
 
Protocol Summary Form
6850
Levin, [LOCATION_009]s
 
Page 28 of 34  
 Ongoing medical assessment
 
In order to minimize the risk associated with the study medication, vital signs (heart rate and blood
pressure) and medication-related side effects will be monitored by [CONTACT_379001]
a week. At each weekly visit the psychiatrist will discuss side effects of medication, review the
Side Effect Questionnaire, will evaluate all reported vital signs and review cardiac risks to
determine whether the dose is being tolerated. Inability to tolerate medication side effects will
result in the reduction or temporary discontinuation of study medications. Patients will be
discontinued from study medication if they 1) cannot tolerate the medication, 2) have a medical or
psychiatric emergency, 3) become hospi[INVESTIGATOR_277292] 4) become pregnant. Patients may be removed
from the trial if they repeatedly miss scheduled appointments or clinical worsening necessitates
more intensive treatment.
 
Twelve weeks after study completion (27 weeks after enrollment) an attempt will be made to
evaluate all participants to explore whether there may be effects of treatment that endure or
emerge after medication discontinuation. In exploratory analyses, outcome at 27 weeks will be
compared between groups originally assigned to medication or placebo on the main primary and
secondary outcomes listed above and on Addiction Severity Index composite scores.
 
Data Safety/Monitoring Plan
 
Patients are closely monitored throughout the trial as described above. Drs. Levin and Carpenter,
the Principal Investigators on this application will be responsible for data and safety monitoring
throughout the trial. In addition to weekly clinic visits, study participation will be monitored
independently by [CONTACT_39109]. The board will meet on an annual basis
to assess the recruitment, progress, safety, adverse events, and serious adverse events
associated with the study. The Data and Safety Monitoring Board will be comprised of three
individuals: 1) [CONTACT_379007], an expert child and adolescent psychopharmacologist with
additional expertise in substance abuse, 2) [CONTACT_379008]- a psychologist who has run
numerous clinical trials and expertise in the evaluating psychological treatments in medically
compromised patients and 3) [CONTACT_379009] â€“ an internist and a graduate of our Addiction
Fellowship Program who has had significant experience working within the framework of clinical
trials evaluating behavioral and pharmacological treatments for substance use disorders.
Individuals on the Safety Monitoring Board will be blind to study medication but can be informed
by [CONTACT_220441]-blinded pharmacist if deemed necessary. If they believe that termination of the trial is
warranted, the blind of all study patients will be broken. 
 
 
Patient Education
 
 
Protocol Summary Form
[ADDRESS_474526] confidentiality
      A Certificate of Confidentiality will be acquired for this study from the National Institute on Drug
Abuse to offer protection for the privacy of subjects by [CONTACT_379002] (e.g., through a subpoena or court order). The Certificate of Confidentiality
will allow investigators and others with access to research records to refuse to disclose
information that could identify subjects in any civil, criminal, administrative, legislative, or other
proceeding, whether at the Federal, State, or local level. The Certificate of Confidentiality is
granted for studies that collect information that, if disclosed, could damage subjectsâ€™ financial,
employability, insurability, or reputation, or have other adverse consequences. 
 
We use coded records (i.e. initials and numbers), store signed consent forms in a locked safe, and
try, to the best of our ability to maintain confidentiality. Only coded records will be entered into the
computer and the security of electronic data is ensured at the level of the server, the user, and the
database. We do, however, point out to prospective patients, that we cannot assure that their drug
histories and other personal records might not become known.
 
TES is a web-based interactive copi[INVESTIGATOR_378964]. While the treatment modules are
stored on a central server maintained by [CONTACT_379003], LLC, we will chose to have the participantâ€™s
responses stored on our computer systems. We will not be utilizing the HealthSim server to
manage and record participantsâ€™ responses. This option will allow the clinical data to be stored on
a secure computer system that will be protected (i.e. behind) by [CONTACT_379004].  
Will the study be conducted under a certificate of confidentiality?
Yes, we will apply for the Certificate of Confidentiality
 
Direct Benefits to Subjects  
 
Direct Benefits to Subjects
Benefits to participants include a comprehensive medical and psychiatric assessment, and
possible improvement in their symptoms of cocaine dependence.
 
Compensation and/or Reimbursement 
 
Protocol Summary Form
6850
Levin, [LOCATION_009]s
 
Page 30 of 34  
  
Will compensation or reimbursement for expenses be offered to subjects?
Yes
Please describe and indicate total amount and schedule of payment(s). 
Include justification for compensation amounts and indicate if there are bonus payments.
  During screening and treatment potential participants receive $[ADDRESS_474527] of a round trip travel on NY Cityâ€™s public transportation. To facilitate the tracking of
medication compliance we pay participants $10 for returning their medication bottle each week of
the trial. The money is paid regardless of compliance status. That is, participants earn $10
whether the bottle is empty or contains unused medication. 
 
Contingency Management Program . The proposed intervention will employ a computer-assisted
version of the Community Reinforcement Approach plus Contingency Management as the
behavioral intervention. Participants will receive copi[INVESTIGATOR_378965] a
prize-bowl, as part of the CM procedures, contingent on the provision of cocaine-free urine. The
CM schedule will follow an escalating schedule as implemented in other contingency management
studies (Higgins et al. 1994). including the one recently completed by [CONTACT_27156] (Martinez,
Carpenter et al., 2011). 
 
     Urine samples will be collected on each visit. Participants receive draws from a prize bowl for
each urine testing negative for benzoylecgonine. Failure to submit a scheduled specimen will be
treated as cocaine positive. Each draw has a probabilistic chance of yielding one of four
outcomes: an encouraging statement (e.g. â€˜good jobâ€™), a small prize valued at $2.50, a large prize
valued at $20, and a jumbo prize valued at $100. The probability for each particular outcome is
fixed for every draw and is based on the relative number of slips for each prize category in the
prize bowl. The expected earning per draw is equal to $2.845 {(0.50*($0) + .418*($2.50) +
.08*($20) + .002*(100)}. 
 
     Using previously employed frameworks the prize bowl will have 500 prize slips. 250 slips will
be the encouraging statement (50% of the total slips), 209 slips will be for small prizes (41.8%), 40
slips will be for large prizes (8%), and 10 slips will be the jumbo prize (0.2%). Participants will earn
[ADDRESS_474528] achieves 2 weeks of abstinence to offset the low rate of reinforcement (low number of draws)
during the beginning of the program. Participants can earn a maximum of 315 draws for submitting
cocaine-free urine samples on 100% of the scheduled treatment visits (45 scheduled visits over
the course of the 15 weeks).
 
References
 
References
Amrhein, P. C., Miller, W. R., Yahne, C. E., Palmer, M., & Fulcher, L. (2003). Client commitment
language during motivational interviewing predicts drug use outcomes. Journal of Consulting and
 
Protocol Summary Form
6850
Levin, [LOCATION_009]s
 
Page 31 of 34  
 Clinical Psychology,71, 862-878.
 
Anderson AL, Reid MS, Li SH, Holmes T, Shemanski L, Slee A, et al. (2009). Modafinil
 for the treatment of cocaine dependence. Drug and Alcohol Dependence, 104, 133-139.
 
Barnes-Holmes D, Hayden E, Barnes-Holmes Y, Stewart I. (2008). The Implicit Relational
Assessment Procedure (IRAP) as a response-time and event-related potentials methodology for
testing natural verbal relations: A preliminary study. Psychological Record, 58, 497-516.
 
 
Bickel WR, Yi R, Landes RD, Hill PF, Baxter C. (2010). Remember the future: Working 
memory training decreases delay discounting among stimulant addicts. Biological
 Psychiatry, 69, 260-265.
 
Bickel WR, Marsch LA, Buchhalter AR, Badger GJ. (2008). Computerized behavior 
therapy for opi[INVESTIGATOR_161118]-dependent outpatients: A randomized clinical trial: Experimental and
 Clinical Psychopharmacology, 26, 132-143.
 
Budney AJ, Higgins ST (1998). A community reinforcement approach plus vouchers
 approach: Treating Cocaine addiction. Therapy manuals for treating drug addition,
 Manual 2. Rockville Md., National Institute on Drug Abuse.
 
Carpenter KM, Schreiber E, Church S, McDowell D. (2006). Drug stroop performance:
relationships with primary substance of abuse and treatment outcome in a drug-dependent
outpatient sample. Addictive Behaviors, 31, 174-181.
 
Carpenter, KM, Smith, JL, Aharonovich, E, Nunes, EV. (2008). Developi[INVESTIGATOR_378966]: Results of a Stage 1 therapy development study. American
Journal of Drug and Alcohol Abuse, 34, 642-652
 
Carroll KM, Ball SA, Martino S, Nich C, Babuscio TA, Nuro KF et al. (2008). Computer-
 assisted delivery of cognitive-behavioral therapy for addiction: A randomized trial of
 CBT4CBT. American Journal of Psychiatry, 165, 881-888.
 
Dutra L, Stathopoulou G, Basden S, Leyro TM, Powers MB, Otto MW. (2008). A meta-analytic
review of psychosocial interventions for substance use disorders. American Journal of Psychiatry,
165, 179-187.
 
Endicott J, Nee J, Harrison W, Blumenthal, R. (1993). Quality of life enjoyment and satisfaction
questionnaire A new measure. Psychopharmacology Bulletin, 29, 321-326
 
Epstein, JN, Johnson, DE and Conners, CK. Conner's Adult ADHD Diagnostic Interview 
for DSM-IV (CAADID). (2001). Multi-Health Systems, Inc., North Tonawanda, [LOCATION_001].
 
 
 
Protocol Summary Form
6850
Levin, [LOCATION_009]s
 
Page 32 of 34  
 Grabowski, J, Rhoades, H, Stotts, A, Cowan, K, Kopecky, C, Dougherty, A, Moeller, FG, 
Hassan, S and Schmitz, J. (2004). Agonist-like or antagonist-like treatment for cocaine 
dependence with methadone for heroin dependence: two double-blind randomized 
clinical trials. Neuropsychopharmacology, 29, 969-981. 
 
Grabowski J, Rhoades H, Schmitz J, Stotts A, Daruzska LA, Creson D, Moeller FG. 
(2001). Dextroamphetamine for cocaine-dependence treatment: a double-blind
 randomized clinical trial. Journal of Clinical Psychopharmacology, 21, 522-526.
 
Guy W. (1976). ECDEU. Assessment Manual for Psychopharmacology. US Department of Health,
Education, and Welfare publication ADM 76-338. Rockville, MD. National Institute of Mental
Health, [ADDRESS_474529], Budney AJ, Bickel WR, Foerg FE, Donham R, Badger GJ. (1994). Incentives Improve
treatment retention and cocaine abstinence in ambulatory cocaine-dependent patients. Archives of
General Psychiatry, 51, 568-576.
 
Kampman KM, Volpi[INVESTIGATOR_9823], Mulvaney F, Rukstalis M, Alterman AI, Pettinati H, et al. 
(2002). Cocaine withdrawal severity and urine toxicology results from treatment entry 
predict outcome in medication trials for cocaine dependence. Addictive Behaviors, 27,
 251-260.
 
Kosten T, Oliveto A, Feingold A, Poling J, Sevarino K, McCance-Katz E, Stine S, Gonzalez G,
Gonsai K. (2003). Desipramine and contigency management for cociane and opi[INVESTIGATOR_378967]. Drug and Alcohol Dependence, 70, 315-325.
 
Levin, FR, Evans, SM, McDowell, DM and Kleber, HD. (1998). Methylphenidate
 treatment for cocaine abusers with adult attention-deficit/hyperactivity disorder: a pi[INVESTIGATOR_378968]. Journal of Clinical Psychiatry, 59, 300-305. 
 
 
Levin FR, Evans SM, Brooks DJ, Garawi F. (2007). Treatment of cocaine dependent
 treatment seekers with adult ADHD: Double-blind comparison of methylphenidate and
 placebo. Drug and Alcohol Dependence, 87, 20-29.
 
 
Litt, M.D., Kadden, R.M., Stephens, R.S. (2005). Copi[INVESTIGATOR_171834]-efficacy in marijuana treatment:
Results from the marijuana treatment project. Journal of Consulting and Clinical Psychology, 73),
1015-1025
 
Martinez D, Carpenter KM, Liu F, Slifstein M, Broft A, Friedman AC, Kumar D, Van Heertum R,
Kleber HD Nunes, E. (2011). Imaging dopamine transmission in cocaine dependence: response to
treatment linked to neurochemistry. The American Journal of Psychiatry, 168, 634 â€“ 641.
NIHMSID: 318824
 
 
Protocol Summary Form
6850
Levin, [LOCATION_009]s
 
Page 33 of 34  
 McLellan AT, Alterman AI, Cacciola J, Metzger D and O'Brien CP. (1992). A new
 measure of substance abuse treatment. Initial studies of the treatment services review. 
Journal of Nervous and Mental Disease, 180, 101-110.
 
Michelson, D, Adler, L, Spencer, T, Reimherr, FW, West, SA, Allen, AJ, Kelsey, D, Wernicke, J,
Dietrich, A and Milton, D. (2003). Atomoxetine in adults with ADHD: two randomized,
placebo-controlled studies. Biological Psychiatry, 53, 112-20.
 
Metzger DS, Dephilippis D, Druley P, O'Brien CP, McLellan AT, Williams JB, Navaline HA,
Dyanick S and Woody GE. (1992). The impact of HIV testing on risk for AIDS behaviors. In L.
Harris (Ed). Problems of Drug Dependence, NIDA Research Monograph 119, National Institute on
Drug Abuse, Rockville, Maryland, 1992.
 
Moeller FG, Schmitz JM, Steinberg JL, Green CM, Reist C, Lau LY, Swann AC, Grabowski J
(2007).Citalopram combined with behavioral therapy reduces cocaine use: A double-blind,
placebo-controlled trial. The American Journal of Drug and Alcohol Abuse, 33, 367-378.
 
Mooney ME, Herin DV, Schmitz JM, Moukaddam N, Green CE, Grabowski J. (2009). Effects of
oral methamphetamine on cocaine use: A randomized, double-blind, placebo-controlled trial. Drug
and Alcohol Dependence, 101, 34-41.
 
Petry, NM, Peirce JM, Stitzer, ML, Blaine J, Roll, JM, Cohen A et al. (2005). Effect of prize-based
incentives on outcomes in stimulant abusers in outpatient psychosocial treatment programs: A
National Drug Abuse Treatment Clinical Trials Network study. Archives of General Psychiatry, 62,
1148-1156.
 
 
Poling J, Oliveto A, Petry N, Sofuoglu M, Gonsai K, Gonzalez G, et al. (2006). Six-month
 trial of bupropi[INVESTIGATOR_378969] a
 methadone-maintained population. Archives of General Psychiatry, 63, 219-228.
 
Rabin, L.A, Roth, R.M., Isquith, P.K., Wishart, H.A., Nutter-Upham, K.E., Pare, N.,
 Flashman, L.A., Saykin, A.J. (2006). Self- and informant reports of executive function on
 the BRIEF-A in MCI and older adults with cognitive complaints. Archives of Clinical
 Neuropsychology, 21, 721-732.
 
Robles E, Vargas PA. (2008) Parameters of delay discounting assessment: Number of trials,
effort, and sequential effects. Behavioural Processes, 78, 285-290.
 
Schmitz JM, Mooney ME, Moeller FG, Stotts AL, Green C, Grabowski J. (2008). Levodopa
pharmacotherapyfor cocaine dependence: Choosing the optimal behavioral therapy platform. Drug
and Alcohol Dependence, 94, 142-150.
 
Sheehan DV, Lecrubier, Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R,
Dunbar GC. (1998). The Mini-International Neuropsychiatric Interview (M.I.N.I): The development
 
Protocol Summary Form
6850
Levin, [LOCATION_009]s
 
Page 34 of 34  
 and validation of structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of
Clinical Psychiatry. Vol.59, 22-33.
 
Sobell, LC and Sobell, MB. (1992). Timeline follow-back: a technique for assessing self-reported
alcohol Consumption in Measuring Alcohol Consumption. Humana Press, Totowa, New Jersey,
41-72.
 
Somoza, E, Baker, S, Himmler, C, LoCastro, J, Mezinskis, JP, Simon, S and Tracy, K. 
(1999). The Brief Substance Craving Scale: Measuring Craving in Clinical Trials.180, 
304.
 
Uploads
 
Upload the entire grant application(s)
Carpenter-Levin FINAL.pdf
Upload copy(ies) of unbolded Consent Form(s)
CF6850v2.pdf
Upload copy(ies) of bolded Consent Form(s)
CF6850v2(BOLD).pdf
Upload evidence of FDA IND approval(s)
CAMP IND.pdf
frl IND holder doc 6850.pdf
Upload copy(ies) of the HIPAA form
PP2AuthorizationResearchStudySeq.pdf
Upload any additional documents that may be related to this study
Memos #6850 9.27.13.pdf
IRB Memo response2 (#6850).pdf
 